Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompleted
NCT03510715Phase 3Updated Dec 29, 2020
Sponsor: Sanofi
Hypercholesterolemia
Brazil, Canada, Denmark, Mexico, Netherlands +5 more
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial CarcinomaTerminated
NCT02608125Phase 1Updated Dec 24, 2020
Sponsor: Principia Biopharma, a Sanofi Company
Solid Tumors · Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
United States, Spain
Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BCompleted
NCT01440946Phase 3Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Hemophilia B
United States, Australia, Ireland, Netherlands, South Africa +1 more
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia ACompleted
NCT01454739Phase 3Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Hemophilia A
United States, Australia, Austria, Belgium, Brazil +17 more
Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell DiseaseCompleted
NCT02447627N/AUpdated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Healthy · Sickle Cell Disease
United States
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsCompleted
NCT02035605Phase 1Updated Dec 19, 2020
Sponsor: Sanofi
Hemophilia A · Hemophilia B
United States, Bulgaria, Russia, Switzerland, United Kingdom
Pharmacokinetics of rFVIIIFc at Two Vial StrengthsCompleted
NCT02083965Phase 1Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Severe Hemophilia A
United States, Australia, United Kingdom
A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's LymphomaCompleted
NCT00002348Phase 2Updated Dec 19, 2020
Sponsor: Genzyme, a Sanofi Company
Lymphoma, Non-Hodgkin · HIV Infections
United States
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia ACompleted
NCT01027377Phase 1Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Severe Hemophilia A
United States, Hong Kong, Israel
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia BCompleted
NCT01425723Phase 3Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Severe Hemophilia B
United States, Australia, Belgium, Brazil, Canada +13 more
Phase I/IIa Study of FIXFc in Hemophilia B PatientsCompleted
NCT00716716Phase 1Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Hemophilia B
United States
Fc factOrs and Real-World hemophiliA Patient-ReporteD OutcomesTerminated
NCT02392156N/AUpdated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Hemophilia A · Hemophilia B
United States
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) ScaleCompleted
NCT02502149Phase 3Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Severe Hemophilia A
United States, Australia, New Zealand
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia BCompleted
NCT01027364Phase 3Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Severe Hemophilia B
United States, Australia, Belgium, Brazil, Canada +12 more
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia ACompleted
NCT01458106Phase 3Updated Dec 19, 2020
Sponsor: Bioverativ Therapeutics Inc.
Hemophilia A
United States, Australia, Hong Kong, Ireland, Netherlands +3 more
Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis PatientsCompleted
NCT03643328NAUpdated Dec 17, 2020
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Staphylococcus Aureus
France
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry DiseaseTerminated
NCT01839526Phase 1Updated Dec 16, 2020
Sponsor: Genzyme, a Sanofi Company
Fabry Disease
United States, Argentina, Austria, Belgium, Brazil +9 more
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19Unknown
NCT04661527Phase 2Updated Dec 16, 2020
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
COVID-19 Drug Treatment
Spain
Calcineurin Inhibitor Sparing After Kidney TransplantationCompleted
NCT01062555Phase 1, Phase 2Updated Dec 14, 2020
Sponsor: University of Minnesota
CNI Side Effects
United States
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced CarcinomaTerminated
NCT00794417Phase 1, Phase 2Updated Dec 10, 2020
Sponsor: Regeneron Pharmaceuticals
Advanced Carcinoma · Non-small Cell Lung Cancer
United States, Canada
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)Completed
NCT00067028Phase 2Updated Dec 8, 2020
Sponsor: M.D. Anderson Cancer Center
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
United States
Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic MyomectomyTerminated
NCT01632202Phase 4Updated Dec 3, 2020
Sponsor: Weill Medical College of Cornell University
Intrauterine Adhesions
United States
Advancing Insulin Prescribing in General PracticeCompleted
NCT00593489NAUpdated Dec 3, 2020
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diabetes Mellitus
Canada
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer PatientsCompleted
NCT00952003Phase 2Updated Nov 30, 2020
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Gastric Cancer · Unresectable
Austria
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)Completed
NCT02407756Phase 2Updated Nov 27, 2020
Sponsor: Regeneron Pharmaceuticals
Atopic Dermatitis
Canada, Czechia, Germany, Hungary, Poland +1 more

Previous page Next page